2019 Future of Hidradenitis Suppurativa R&D Pipeline Drugs and Companies- Analysis of Global Hidradenitis Suppurativa Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments
The global demand for Hidradenitis Suppurativa treatment options is emerging rapidly driven by consumption in major emerging markets. As more growth opportunities will turn up over the medium to long term future, a large number of companies are working on Hidradenitis Suppurativa pipeline. Companies quickly adapting to the change and moving their products to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and inadequate financial support are holding some of the Hidradenitis Suppurativa pipeline companies from advancing their products into Phase 3 or Phase 4.
Hidradenitis Suppurativa Report Description
The H1 2019 pipeline review report on Hidradenitis Suppurativa pipeline is a comprehensive study on the candidates in development across different phases worldwide. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Hidradenitis Suppurativa pipeline compounds.
The Hidradenitis Suppurativa pipeline guide presents information on all active drugs currently being developed for Hidradenitis Suppurativa. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.
Details of current status, R&D progress and latest developments for every Hidradenitis Suppurativa pipeline candidate are analyzed.
Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Hidradenitis Suppurativa drug candidates.
Drug development companies, collaborators, originating companies, license providers and universities participating in the Hidradenitis Suppurativa product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.
The report assists in identifying potential upcoming companies and drugs in Hidradenitis Suppurativa pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.
VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.
Scope of Hidradenitis Suppurativa pipeline report includes
REASONS TO BUY
Hidradenitis Suppurativa Report Description
The H1 2019 pipeline review report on Hidradenitis Suppurativa pipeline is a comprehensive study on the candidates in development across different phases worldwide. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Hidradenitis Suppurativa pipeline compounds.
The Hidradenitis Suppurativa pipeline guide presents information on all active drugs currently being developed for Hidradenitis Suppurativa. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.
Details of current status, R&D progress and latest developments for every Hidradenitis Suppurativa pipeline candidate are analyzed.
Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Hidradenitis Suppurativa drug candidates.
Drug development companies, collaborators, originating companies, license providers and universities participating in the Hidradenitis Suppurativa product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.
The report assists in identifying potential upcoming companies and drugs in Hidradenitis Suppurativa pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.
VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.
Scope of Hidradenitis Suppurativa pipeline report includes
- An overview of Hidradenitis Suppurativa disease including symptoms, causes, diagnosis and available treatment options is provided.
- Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc
- Phase wise count of pipeline compounds
- Company wise list of pipeline compounds
- Mechanism of Action wise pipeline compounds
- For each pipeline product, the following details are provided-
- Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)
- Current status of development
- Drug overview
- Mechanism of Action
- Pre-clinical and Clinical Trials
REASONS TO BUY
- The report is designed to help industry executives promote the success and continued growth of their organizations
- Get clear understanding of the entire Hidradenitis Suppurativa pipeline, with details on active projects
- Stay ahead of the competition through comprehensive knowledge of Hidradenitis Suppurativa pipeline progress
- Get in detail information of each product with updated information on each project along with key milestones
- Gain clear insights into the market through in-depth strategic analysis review
- Know the list of companies participating in global Hidradenitis Suppurativa pipeline along with progress of each of the company’s products and information on associations/collaborations/licensing data
- Get trial information for each pipeline product under development
- Understand the pipeline structure in terms of mechanism of Action, phase and company
1. TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2. GLOBAL HIDRADENITIS SUPPURATIVA PIPELINE OVERVIEW
2.1 Key Findings, 2019
2.2 Disease Overview
2.3 Report Guide and Research Methodology
3. EXECUTIVE SUMMARY
3.1 Hidradenitis Suppurativa Drugs under active development, H1- 2019
3.2 Pipeline Drugs in Early Stage of Development (Pre-clinical, Discovery, Phase 1 and Phase 2)
3.3 Pipeline Drugs in Advanced Stage of Development (Phase 3, Pre-registration)
3.4 Companies involved in Hidradenitis Suppurativa pipeline, H1- 2019
3.5 Mechanism of Action wise Hidradenitis Suppurativa Pipeline Candidates
4. ABBVIE INC HIDRADENITIS SUPPURATIVA PIPELINE DETAILS
4.1 AbbVie Inc Business Profile
4.2 AbbVie Inc Hidradenitis Suppurativa Drug Details
4.2.1 Drug Snapshot
4.2.1.1 Originator
4.2.1.2 Collaborator/Co-Developer
4.2.1.3 Route of Administration
4.2.1.4 Orphan Drug/Fast Track/Special Designation
4.2.1.5 Area
4.2.1.6 Type of Molecular Entity
4.3 Current Status
4.4 Drug Overview
4.5 Drug Mechanism of Action
4.6 Clinical/Pre-clinical Trial Details
4.7 Latest Drug Developments
5. CELGENE CORP HIDRADENITIS SUPPURATIVA PIPELINE DETAILS
5.1 Celgene Corp Business Profile
5.2 Celgene Corp Hidradenitis Suppurativa Drug Details
5.2.1 Drug Snapshot
5.2.1.1 Originator
5.2.1.2 Collaborator/Co-Developer
5.2.1.3 Route of Administration
5.2.1.4 Orphan Drug/Fast Track/Special Designation
5.2.1.5 Area
5.2.1.6 Type of Molecular Entity
5.3 Current Status
5.4 Drug Overview
5.5 Drug Mechanism of Action
5.6 Clinical/Pre-clinical Trial Details
5.7 Latest Drug Developments
6. CHEMOCENTRYX INC HIDRADENITIS SUPPURATIVA PIPELINE DETAILS
6.1 ChemoCentryx Inc Business Profile
6.2 ChemoCentryx Inc Hidradenitis Suppurativa Drug Details
6.2.1 Drug Snapshot
6.2.1.1 Originator
6.2.1.2 Collaborator/Co-Developer
6.2.1.3 Route of Administration
6.2.1.4 Orphan Drug/Fast Track/Special Designation
6.2.1.5 Area
6.2.1.6 Type of Molecular Entity
6.3 Current Status
6.4 Drug Overview
6.5 Drug Mechanism of Action
6.6 Clinical/Pre-clinical Trial Details
6.7 Latest Drug Developments
7. FRESENIUS SE & CO KGAA HIDRADENITIS SUPPURATIVA PIPELINE DETAILS
7.1 Fresenius SE & Co KGaA Business Profile
7.2 Fresenius SE & Co KGaA Hidradenitis Suppurativa Drug Details
7.2.1 Drug Snapshot
7.2.1.1 Originator
7.2.1.2 Collaborator/Co-Developer
7.2.1.3 Route of Administration
7.2.1.4 Orphan Drug/Fast Track/Special Designation
7.2.1.5 Area
7.2.1.6 Type of Molecular Entity
7.3 Current Status
7.4 Drug Overview
7.5 Drug Mechanism of Action
7.6 Clinical/Pre-clinical Trial Details
7.7 Latest Drug Developments
8. IMMUNWORK INC HIDRADENITIS SUPPURATIVA PIPELINE DETAILS
8.1 Immunwork Inc Business Profile
8.2 Immunwork Inc Hidradenitis Suppurativa Drug Details
8.2.1 Drug Snapshot
8.2.1.1 Originator
8.2.1.2 Collaborator/Co-Developer
8.2.1.3 Route of Administration
8.2.1.4 Orphan Drug/Fast Track/Special Designation
8.2.1.5 Area
8.2.1.6 Type of Molecular Entity
8.3 Current Status
8.4 Drug Overview
8.5 Drug Mechanism of Action
8.6 Clinical/Pre-clinical Trial Details
8.7 Latest Drug Developments
9. INCYTE CORP HIDRADENITIS SUPPURATIVA PIPELINE DETAILS
9.1 Incyte Corp Business Profile
9.2 Incyte Corp Hidradenitis Suppurativa Drug Details
9.2.1 Drug Snapshot
9.2.1.1 Originator
9.2.1.2 Collaborator/Co-Developer
9.2.1.3 Route of Administration
9.2.1.4 Orphan Drug/Fast Track/Special Designation
9.2.1.5 Area
9.2.1.6 Type of Molecular Entity
9.3 Current Status
9.4 Drug Overview
9.5 Drug Mechanism of Action
9.6 Clinical/Pre-clinical Trial Details
9.7 Latest Drug Developments
10. INFLARX NV HIDRADENITIS SUPPURATIVA PIPELINE DETAILS
10.1 InflaRx NV Business Profile
10.2 InflaRx NV Hidradenitis Suppurativa Drug Details
10.2.1 Drug Snapshot
10.2.1.1 Originator
10.2.1.2 Collaborator/Co-Developer
10.2.1.3 Route of Administration
10.2.1.4 Orphan Drug/Fast Track/Special Designation
10.2.1.5 Area
10.2.1.6 Type of Molecular Entity
10.3 Current Status
10.4 Drug Overview
10.5 Drug Mechanism of Action
10.6 Clinical/Pre-clinical Trial Details
10.7 Latest Drug Developments
11. INNOVATION PHARMACEUTICALS INC HIDRADENITIS SUPPURATIVA PIPELINE DETAILS
11.1 Innovation Pharmaceuticals Inc Business Profile
11.2 Innovation Pharmaceuticals Inc Hidradenitis Suppurativa Drug Details
11.2.1 Drug Snapshot
11.2.1.1 Originator
11.2.1.2 Collaborator/Co-Developer
11.2.1.3 Route of Administration
11.2.1.4 Orphan Drug/Fast Track/Special Designation
11.2.1.5 Area
11.2.1.6 Type of Molecular Entity
11.3 Current Status
11.4 Drug Overview
11.5 Drug Mechanism of Action
11.6 Clinical/Pre-clinical Trial Details
11.7 Latest Drug Developments
12. NOVARTIS AG HIDRADENITIS SUPPURATIVA PIPELINE DETAILS
12.1 Novartis AG Business Profile
12.2 Novartis AG Hidradenitis Suppurativa Drug Details
12.2.1 Drug Snapshot
12.2.1.1 Originator
12.2.1.2 Collaborator/Co-Developer
12.2.1.3 Route of Administration
12.2.1.4 Orphan Drug/Fast Track/Special Designation
12.2.1.5 Area
12.2.1.6 Type of Molecular Entity
12.3 Current Status
12.4 Drug Overview
12.5 Drug Mechanism of Action
12.6 Clinical/Pre-clinical Trial Details
12.7 Latest Drug Developments
13. UCB SA HIDRADENITIS SUPPURATIVA PIPELINE DETAILS
13.1 UCB SA Business Profile
13.2 UCB SA Hidradenitis Suppurativa Drug Details
13.2.1 Drug Snapshot
13.2.1.1 Originator
13.2.1.2 Collaborator/Co-Developer
13.2.1.3 Route of Administration
13.2.1.4 Orphan Drug/Fast Track/Special Designation
13.2.1.5 Area
13.2.1.6 Type of Molecular Entity
13.3 Current Status
13.4 Drug Overview
13.5 Drug Mechanism of Action
13.6 Clinical/Pre-clinical Trial Details
13.7 Latest Drug Developments
14. XBIOTECH INC HIDRADENITIS SUPPURATIVA PIPELINE DETAILS
14.1 XBiotech Inc Business Profile
14.2 XBiotech Inc Hidradenitis Suppurativa Drug Details
14.2.1 Drug Snapshot
14.2.1.1 Originator
14.2.1.2 Collaborator/Co-Developer
14.2.1.3 Route of Administration
14.2.1.4 Orphan Drug/Fast Track/Special Designation
14.2.1.5 Area
14.2.1.6 Type of Molecular Entity
14.3 Current Status
14.4 Drug Overview
14.5 Drug Mechanism of Action
14.6 Clinical/Pre-clinical Trial Details
14.7 Latest Drug Developments
15. LATEST HIDRADENITIS SUPPURATIVA DRUG PIPELINE DEVELOPMENTS, 2019
16. APPENDIX
16.1 About Us
16.2 Sources and Methodology
16.3 Contact Information
1.1 List of Tables
1.2 List of Figures
2. GLOBAL HIDRADENITIS SUPPURATIVA PIPELINE OVERVIEW
2.1 Key Findings, 2019
2.2 Disease Overview
2.3 Report Guide and Research Methodology
3. EXECUTIVE SUMMARY
3.1 Hidradenitis Suppurativa Drugs under active development, H1- 2019
3.2 Pipeline Drugs in Early Stage of Development (Pre-clinical, Discovery, Phase 1 and Phase 2)
3.3 Pipeline Drugs in Advanced Stage of Development (Phase 3, Pre-registration)
3.4 Companies involved in Hidradenitis Suppurativa pipeline, H1- 2019
3.5 Mechanism of Action wise Hidradenitis Suppurativa Pipeline Candidates
4. ABBVIE INC HIDRADENITIS SUPPURATIVA PIPELINE DETAILS
4.1 AbbVie Inc Business Profile
4.2 AbbVie Inc Hidradenitis Suppurativa Drug Details
4.2.1 Drug Snapshot
4.2.1.1 Originator
4.2.1.2 Collaborator/Co-Developer
4.2.1.3 Route of Administration
4.2.1.4 Orphan Drug/Fast Track/Special Designation
4.2.1.5 Area
4.2.1.6 Type of Molecular Entity
4.3 Current Status
4.4 Drug Overview
4.5 Drug Mechanism of Action
4.6 Clinical/Pre-clinical Trial Details
4.7 Latest Drug Developments
5. CELGENE CORP HIDRADENITIS SUPPURATIVA PIPELINE DETAILS
5.1 Celgene Corp Business Profile
5.2 Celgene Corp Hidradenitis Suppurativa Drug Details
5.2.1 Drug Snapshot
5.2.1.1 Originator
5.2.1.2 Collaborator/Co-Developer
5.2.1.3 Route of Administration
5.2.1.4 Orphan Drug/Fast Track/Special Designation
5.2.1.5 Area
5.2.1.6 Type of Molecular Entity
5.3 Current Status
5.4 Drug Overview
5.5 Drug Mechanism of Action
5.6 Clinical/Pre-clinical Trial Details
5.7 Latest Drug Developments
6. CHEMOCENTRYX INC HIDRADENITIS SUPPURATIVA PIPELINE DETAILS
6.1 ChemoCentryx Inc Business Profile
6.2 ChemoCentryx Inc Hidradenitis Suppurativa Drug Details
6.2.1 Drug Snapshot
6.2.1.1 Originator
6.2.1.2 Collaborator/Co-Developer
6.2.1.3 Route of Administration
6.2.1.4 Orphan Drug/Fast Track/Special Designation
6.2.1.5 Area
6.2.1.6 Type of Molecular Entity
6.3 Current Status
6.4 Drug Overview
6.5 Drug Mechanism of Action
6.6 Clinical/Pre-clinical Trial Details
6.7 Latest Drug Developments
7. FRESENIUS SE & CO KGAA HIDRADENITIS SUPPURATIVA PIPELINE DETAILS
7.1 Fresenius SE & Co KGaA Business Profile
7.2 Fresenius SE & Co KGaA Hidradenitis Suppurativa Drug Details
7.2.1 Drug Snapshot
7.2.1.1 Originator
7.2.1.2 Collaborator/Co-Developer
7.2.1.3 Route of Administration
7.2.1.4 Orphan Drug/Fast Track/Special Designation
7.2.1.5 Area
7.2.1.6 Type of Molecular Entity
7.3 Current Status
7.4 Drug Overview
7.5 Drug Mechanism of Action
7.6 Clinical/Pre-clinical Trial Details
7.7 Latest Drug Developments
8. IMMUNWORK INC HIDRADENITIS SUPPURATIVA PIPELINE DETAILS
8.1 Immunwork Inc Business Profile
8.2 Immunwork Inc Hidradenitis Suppurativa Drug Details
8.2.1 Drug Snapshot
8.2.1.1 Originator
8.2.1.2 Collaborator/Co-Developer
8.2.1.3 Route of Administration
8.2.1.4 Orphan Drug/Fast Track/Special Designation
8.2.1.5 Area
8.2.1.6 Type of Molecular Entity
8.3 Current Status
8.4 Drug Overview
8.5 Drug Mechanism of Action
8.6 Clinical/Pre-clinical Trial Details
8.7 Latest Drug Developments
9. INCYTE CORP HIDRADENITIS SUPPURATIVA PIPELINE DETAILS
9.1 Incyte Corp Business Profile
9.2 Incyte Corp Hidradenitis Suppurativa Drug Details
9.2.1 Drug Snapshot
9.2.1.1 Originator
9.2.1.2 Collaborator/Co-Developer
9.2.1.3 Route of Administration
9.2.1.4 Orphan Drug/Fast Track/Special Designation
9.2.1.5 Area
9.2.1.6 Type of Molecular Entity
9.3 Current Status
9.4 Drug Overview
9.5 Drug Mechanism of Action
9.6 Clinical/Pre-clinical Trial Details
9.7 Latest Drug Developments
10. INFLARX NV HIDRADENITIS SUPPURATIVA PIPELINE DETAILS
10.1 InflaRx NV Business Profile
10.2 InflaRx NV Hidradenitis Suppurativa Drug Details
10.2.1 Drug Snapshot
10.2.1.1 Originator
10.2.1.2 Collaborator/Co-Developer
10.2.1.3 Route of Administration
10.2.1.4 Orphan Drug/Fast Track/Special Designation
10.2.1.5 Area
10.2.1.6 Type of Molecular Entity
10.3 Current Status
10.4 Drug Overview
10.5 Drug Mechanism of Action
10.6 Clinical/Pre-clinical Trial Details
10.7 Latest Drug Developments
11. INNOVATION PHARMACEUTICALS INC HIDRADENITIS SUPPURATIVA PIPELINE DETAILS
11.1 Innovation Pharmaceuticals Inc Business Profile
11.2 Innovation Pharmaceuticals Inc Hidradenitis Suppurativa Drug Details
11.2.1 Drug Snapshot
11.2.1.1 Originator
11.2.1.2 Collaborator/Co-Developer
11.2.1.3 Route of Administration
11.2.1.4 Orphan Drug/Fast Track/Special Designation
11.2.1.5 Area
11.2.1.6 Type of Molecular Entity
11.3 Current Status
11.4 Drug Overview
11.5 Drug Mechanism of Action
11.6 Clinical/Pre-clinical Trial Details
11.7 Latest Drug Developments
12. NOVARTIS AG HIDRADENITIS SUPPURATIVA PIPELINE DETAILS
12.1 Novartis AG Business Profile
12.2 Novartis AG Hidradenitis Suppurativa Drug Details
12.2.1 Drug Snapshot
12.2.1.1 Originator
12.2.1.2 Collaborator/Co-Developer
12.2.1.3 Route of Administration
12.2.1.4 Orphan Drug/Fast Track/Special Designation
12.2.1.5 Area
12.2.1.6 Type of Molecular Entity
12.3 Current Status
12.4 Drug Overview
12.5 Drug Mechanism of Action
12.6 Clinical/Pre-clinical Trial Details
12.7 Latest Drug Developments
13. UCB SA HIDRADENITIS SUPPURATIVA PIPELINE DETAILS
13.1 UCB SA Business Profile
13.2 UCB SA Hidradenitis Suppurativa Drug Details
13.2.1 Drug Snapshot
13.2.1.1 Originator
13.2.1.2 Collaborator/Co-Developer
13.2.1.3 Route of Administration
13.2.1.4 Orphan Drug/Fast Track/Special Designation
13.2.1.5 Area
13.2.1.6 Type of Molecular Entity
13.3 Current Status
13.4 Drug Overview
13.5 Drug Mechanism of Action
13.6 Clinical/Pre-clinical Trial Details
13.7 Latest Drug Developments
14. XBIOTECH INC HIDRADENITIS SUPPURATIVA PIPELINE DETAILS
14.1 XBiotech Inc Business Profile
14.2 XBiotech Inc Hidradenitis Suppurativa Drug Details
14.2.1 Drug Snapshot
14.2.1.1 Originator
14.2.1.2 Collaborator/Co-Developer
14.2.1.3 Route of Administration
14.2.1.4 Orphan Drug/Fast Track/Special Designation
14.2.1.5 Area
14.2.1.6 Type of Molecular Entity
14.3 Current Status
14.4 Drug Overview
14.5 Drug Mechanism of Action
14.6 Clinical/Pre-clinical Trial Details
14.7 Latest Drug Developments
15. LATEST HIDRADENITIS SUPPURATIVA DRUG PIPELINE DEVELOPMENTS, 2019
16. APPENDIX
16.1 About Us
16.2 Sources and Methodology
16.3 Contact Information
